Alzheimer's disease drug development pipeline: 2025

IF 6.8 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2025-06-03 DOI:10.1002/trc2.70098

Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Amanda M. Leisgang-Osse, Feixiong Cheng

{"title":"Alzheimer's disease drug development pipeline: 2025","authors":"Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Amanda M. Leisgang-Osse, Feixiong Cheng","doi":"10.1002/trc2.70098","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline. Currently, there are 138 drugs being assessed in 182 clinical trials in the AD pipeline. Biological disease-targeted therapies (DTTs) comprise 30% of the pipeline; small molecule DTTs account for 43% of the pipeline; drugs addressing cognitive enhancement account for 14% of the pipeline; and drugs aiming to ameliorate neuropsychiatric symptoms in participants with AD contribute 11% of the pipeline. Biomarkers are among the primary outcomes of 27% of active trials. Repurposed agents represent 33% of the pipeline agents. The pipeline has more trials and more drugs compared to the 2024 pipeline.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>The 2025 Alzheimer's disease drug development pipeline hosts 182 trials and 138 novel drugs.</li>\n \n <li>The 2025 Alzheimer's disease drug development pipeline is diverse, with agents that address 15 basic disease processes.</li>\n \n <li>The 2025 Alzheimer's disease drug development pipeline has more trials and more drugs than the 2024 pipeline.</li>\n \n <li>Biomarkers play an important role in current trials to determine trial eligibility and as outcomes of trials.</li>\n \n <li>Repurposed agents comprise approximately one-third of the agents and trials in the 2025 Alzheimer's disease drug development pipeline.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70098","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline. Currently, there are 138 drugs being assessed in 182 clinical trials in the AD pipeline. Biological disease-targeted therapies (DTTs) comprise 30% of the pipeline; small molecule DTTs account for 43% of the pipeline; drugs addressing cognitive enhancement account for 14% of the pipeline; and drugs aiming to ameliorate neuropsychiatric symptoms in participants with AD contribute 11% of the pipeline. Biomarkers are among the primary outcomes of 27% of active trials. Repurposed agents represent 33% of the pipeline agents. The pipeline has more trials and more drugs compared to the 2024 pipeline.

Highlights

The 2025 Alzheimer's disease drug development pipeline hosts 182 trials and 138 novel drugs.
The 2025 Alzheimer's disease drug development pipeline is diverse, with agents that address 15 basic disease processes.
The 2025 Alzheimer's disease drug development pipeline has more trials and more drugs than the 2024 pipeline.
Biomarkers play an important role in current trials to determine trial eligibility and as outcomes of trials.
Repurposed agents comprise approximately one-third of the agents and trials in the 2025 Alzheimer's disease drug development pipeline.

Abstract Image

查看原文本刊更多论文

阿尔茨海默病药物开发管道：2025年

阿尔茨海默病（AD）的临床试验必须在clinicaltrials.gov上注册。注册表提供了与计划的临床试验相关的各种类型的信息。我们对临床试验网站进行评估，以记录和比较AD管道中药物开发的各个方面。目前，有138种药物正在进行182项临床试验。生物疾病靶向治疗（dtt）占管道的30%；小分子dts占管道的43%；针对认知增强的药物占了14%；旨在改善阿尔茨海默病患者神经精神症状的药物贡献了11%。生物标志物是27%正在进行的试验的主要结果之一。重新利用的药剂占管线药剂的33%。与2024年的管道相比，该管道有更多的试验和更多的药物。2025年阿尔茨海默病药物开发管道将进行182项试验和138种新药。2025年阿尔茨海默病药物开发管道是多样化的，药物针对15种基本疾病过程。2025年的阿尔茨海默病药物开发管道比2024年的管道有更多的试验和更多的药物。生物标志物在当前的试验中起着重要的作用，以确定试验的资格和作为试验的结果。在2025年阿尔茨海默病药物开发管道中，重新利用的药物约占药物和试验的三分之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.